Get the Stockscreener App
22.96
0.79%
-0.10
Summit Therapeutics Inc stock is traded at $22.96, with a volume of 674.47K.
It is down -0.79% in the last 24 hours and up +3.52% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$23.06
Open:
$23.87
24h Volume:
674.47K
Relative Volume:
0.32
Market Cap:
$17.01B
Revenue:
$956.00K
Net Income/Loss:
$-196.68M
P/E Ratio:
-95.67
EPS:
-0.24
Net Cash Flow:
$-113.02M
1W Performance:
+7.06%
1M Performance:
+3.52%
6M Performance:
+71.50%
1Y Performance:
+456.64%
1-Day Range:
$22.75
$24.18
1-Week Range:
$20.43
$24.18
52-Week Range:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
22.93 | 17.01B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.69 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.46 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.77 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.90 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
116.94 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Summit Therapeutics (SMMT) Expected to Announce Earnings on Tuesday - MarketBeat
Summit Therapeutics Earnings: Critical Q4 Financial Report & Strategic Roadmap Reveal Coming February 24 - StockTitan
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.8%Time to Sell? - MarketBeat
3 Stocks That Could Trounce the Market in 2025 - Yahoo Finance
Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.8%Here's What Happened - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
U.S. investors, Big Pharma race to find new medicines in China - CNBC
Summit Therapeutics (NASDAQ:SMMT) Shares Up 6%Here's Why - MarketBeat
SG Americas Securities LLC Sells 19,587 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
When the Price of (SMMT) Talks, People Listen - Stock Traders Daily
abrdn plc Increases Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024 - Citeline News & Insights
Calamos Advisors LLC Has $425,000 Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Is Summit Therapeutics a Millionaire Maker? - Nasdaq
2 Stocks That Could Soar Again in 2025 - MSN
Why Summit Therapeutics Inc. (SMMT) Is Among the Best Healthcare Stocks To Buy According to Analysts - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.4%Should You Sell? - MarketBeat
The drug industry is having its own DeepSeek moment | Mint - Mint
The Drug Industry Is Having Its Own DeepSeek Moment - The Wall Street Journal
China Universal Asset Management Co. Ltd. Acquires 17,014 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $33.57 Average Price Target from Brokerages - MarketBeat
Five Pine Wealth Management Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (SMMT): Jim Cramer Calls It a ‘Very Big Spec’ - Insider Monkey
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There' - Benzinga India
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? - MSN
Griffin Asset Management Inc. Purchases 42,900 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Lightning Round: I don't want to sell Adobe down here, says Jim Cramer - MSN
(SMMT) Investment Report - Stock Traders Daily
Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? - Yahoo Finance
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond - The Motley Fool
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):